Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 18/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15588224 | 0.88 | FLT4 (0.53) | KITFLT3FLT4 | |
| SCHEMBL15524004 | 0.81 | PTK2 (0.67) | PTK2 | |
| SCHEMBL12478019 | 0.76 | PTK2 (0.59) | PTK2 | |
| SCHEMBL17027297 | 0.76 | RXFP1 (0.40) | PTK2FLT4 | |
| SCHEMBL17027317 | 0.75 | PTK2 (0.36) | PTK2FLT4 | |
| SCHEMBL14643090 | 0.75 | PTK2 (0.58) | PTK2 | |
| SCHEMBL15524753 | 0.72 | FLT3 (0.58) | KITFLT3PTK2FLT4 | |
| SCHEMBL15524335 | 0.72 | BTK (0.42) | PTK2FLT4 | |
| SCHEMBL15506924 | 0.71 | FLT4 (0.68) | KITFLT3PTK2FLT4 | |
| SCHEMBL15524527 | 0.71 | PTK2 (0.44) | PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20090068168-A1 | SUBSTITUTED AMINO ALCOHOLS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068168-A1 | SUBSTITUTED AMINO ALCOHOLS | GOT1, AADAT, ADH1A | KIT 3706/4885FLT3 1292/4885PTK2 3451/4885 |
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | KIT 28/4885FLT3 55/4885PTK2 240/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | KIT 18/4885FLT3 33/4885PTK2 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.